Zealand Pharma appoints Lilly’s Utpal Singh as CSO

24 April 2025

Denmark’s Zealand Pharma (CPH: ZEAL), a company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Utpal Singh as chief scientific officer.

Mr Singh will join the executive team to lead discovery research and translational sciences at Zealand Pharma.

He brings nearly 25 years of pharmaceutical industry experience spanning the full drug discovery and development lifecycle. Most recently, he served as senior vice president of small molecule discovery at Eli Lilly (NYSE: LLY), where he led the transformation of the discovery engine by building new capabilities and strategic partnerships to advance a focused portfolio. His team contributed to the discovery of numerous clinical candidates across multiple therapeutic areas.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK